NO854355L - Immunogent kompleks, en fremgangsmaate til fremstilling derav og anvendelse av komplekset som en immunstimulator, vaksiner og reagenser. - Google Patents

Immunogent kompleks, en fremgangsmaate til fremstilling derav og anvendelse av komplekset som en immunstimulator, vaksiner og reagenser.

Info

Publication number
NO854355L
NO854355L NO854355A NO854355A NO854355L NO 854355 L NO854355 L NO 854355L NO 854355 A NO854355 A NO 854355A NO 854355 A NO854355 A NO 854355A NO 854355 L NO854355 L NO 854355L
Authority
NO
Norway
Prior art keywords
complex
peptides
proteins
preparing
carrier molecule
Prior art date
Application number
NO854355A
Other languages
English (en)
Other versions
NO167076B (no
NO167076C (no
Inventor
Bror Morein
Original Assignee
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein filed Critical Bror Morein
Publication of NO854355L publication Critical patent/NO854355L/no
Publication of NO167076B publication Critical patent/NO167076B/no
Publication of NO167076C publication Critical patent/NO167076C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO854355A 1984-11-01 1985-10-31 Fremgangsmaate til fremstilling av et immunogent kompleks som kan anvendes til immunostimulerende preparat, vaksine og reagens. NO167076C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8405493A SE8405493D0 (sv) 1984-11-01 1984-11-01 Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel

Publications (3)

Publication Number Publication Date
NO854355L true NO854355L (no) 1986-05-02
NO167076B NO167076B (no) 1991-06-24
NO167076C NO167076C (no) 1991-10-02

Family

ID=20357588

Family Applications (1)

Application Number Title Priority Date Filing Date
NO854355A NO167076C (no) 1984-11-01 1985-10-31 Fremgangsmaate til fremstilling av et immunogent kompleks som kan anvendes til immunostimulerende preparat, vaksine og reagens.

Country Status (17)

Country Link
US (1) US5254339A (no)
EP (2) EP0180564B1 (no)
JP (2) JPH07116056B2 (no)
AT (1) ATE65186T1 (no)
AU (2) AU589915B2 (no)
CA (2) CA1275042A (no)
DE (1) DE3583485D1 (no)
DK (1) DK166653B1 (no)
ES (1) ES8701497A1 (no)
FI (1) FI86801C (no)
IE (1) IE58530B1 (no)
NO (1) NO167076C (no)
NZ (1) NZ213899A (no)
PT (1) PT81384B (no)
SE (1) SE8405493D0 (no)
WO (1) WO1987002250A1 (no)
ZA (1) ZA858157B (no)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
FR2598434B1 (fr) * 1986-05-12 1988-09-16 Pf Medicament Nouveaux immunomodulateurs obtenus par hemisynthese a partir d'un polysaccharide bacterien isole d'une souche mutante non capsulee de klebsiella pneumoniae
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
FR2614306B1 (fr) * 1987-04-22 1989-07-28 Pf Medicament Nouveau derive de d.25, procede de preparation, utilisation a titre d'agent immunostimulant et compositions pharmaceutiques le contenant.
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
JPH049015U (no) * 1990-05-09 1992-01-27
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
EP0598816B1 (en) * 1991-08-15 1999-06-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
JP4129544B2 (ja) * 1993-03-29 2008-08-06 ファイザー・インク サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
JPH0756123A (ja) * 1993-08-20 1995-03-03 Nakanishi Opt:Kk 眼鏡フレーム
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996023061A2 (en) * 1995-01-27 1996-08-01 Genencor International, Inc. Surfactant-based enzyme extraction process
US20030190323A1 (en) * 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
EP1801591B1 (en) 1997-08-04 2016-12-28 Advanced Life Science Institute, Inc. Methods for detection or measurement of viruses
ID29082A (id) * 1998-09-22 2001-07-26 Molecular Express Inc Komposisi liposom imunogenik
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
KR20060116041A (ko) 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
MXPA02008748A (es) 2000-03-17 2003-02-24 Upjohn Co Materiales y metodos para vacuna antisalmonella.
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2002211669A1 (en) 2000-10-12 2002-04-22 Robert Corcoran Purification of substance by reaction affinity chromatography
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
US20140248273A1 (en) 2001-09-08 2014-09-04 Jos van Strijp Vaccine based on staphylococcal superantigen-like 3 protein (ssl3)
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2477312C (en) * 2002-03-01 2013-02-26 Trillium Therapeutics Inc. Use of soluble fgl2 as an immunosuppressant
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
JP2005535350A (ja) 2002-08-12 2005-11-24 アクゾ・ノベル・エヌ・ベー ストレプトコッカス・ユベリス蛋白質、前記蛋白質をコードする核酸配列及び乳腺炎ワクチンにおけるその使用
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
EP1578443B1 (en) 2002-11-20 2011-01-12 Bestewil Holding B.V. Compositions comprising antigen-complexes, method for making same as well as methods of using the antigen-complexes for vaccination
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
WO2006133879A2 (en) 2005-06-16 2006-12-21 Universiteit Gent Vaccines for immunization against helicobacter
EP1912665B1 (en) 2005-07-28 2011-01-26 Pfizer Products Inc. Vaccine against feline calicivirus (fcv) comprising a fcv capsid protein or an isolated fcv capsid protein comprising protein sequence seq id no: 13 or protein sequences having at least 95% identity thereto.
BRPI0616328A2 (pt) 2005-10-07 2011-06-14 Pfizer Prod Inc vacinas e mÉtodos para tratar influenza canino
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
DK3300743T3 (da) 2006-12-27 2023-07-24 Zoetis Services Llc Fremgangsmåder til indgivelse af vaccine
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
AU2008340319A1 (en) * 2007-12-21 2009-07-02 Wyeth Llc Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
WO2011048041A1 (en) 2009-10-19 2011-04-28 Intervet International B.V. Streptococcal combi-vaccine
JP2013507944A (ja) 2009-10-22 2013-03-07 ウニヴェルシテート・ライプツィヒ 汎血球減少症罹患仔ウシにおけるサーコウイルス（ｃｉｒｃｏｖｉｒｕｓ）の特定
ES2588225T3 (es) 2010-04-21 2016-10-31 Pharmaq As Secuencias de ácido nucleico de un virus de pece y el uso de las mismas
EP2569009B1 (en) 2010-05-14 2019-10-09 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
ES2614807T3 (es) 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
CN103052401A (zh) 2010-07-23 2013-04-17 伊斯克诺瓦公司 流感疫苗
HUE052850T2 (hu) 2010-08-23 2021-05-28 Wyeth Llc Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
MX362802B (es) 2010-09-10 2019-02-13 Wyeth Llc Star Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis.
EP2635593B1 (en) 2010-11-05 2016-09-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Vaccines for preventing meningococcal infections
NO2640832T3 (no) 2010-11-15 2018-05-19
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
EP2648746A1 (en) 2010-12-08 2013-10-16 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
SI3150222T1 (sl) 2010-12-22 2020-02-28 Wyeth Llc Stabilni imunogenski sestavki antigenov staphylococcus aureus
JP5980810B2 (ja) 2010-12-29 2016-09-07 インターベット インターナショナル ベー． フェー． イヌバベシア症ワクチン抗原
CA2822115C (en) 2010-12-29 2022-05-24 Intervet International B.V. Salmonid alphavirus protein e2
WO2012131099A1 (en) 2011-03-31 2012-10-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
DK2694094T3 (da) 2011-04-07 2017-11-13 Neovacs FREMGANGSMÅDE TIL BEHANDLING AF IFN-alpha-RELATEREDE TILSTANDE
WO2012158643A1 (en) 2011-05-13 2012-11-22 Ah Usa 42 Llc Hendra and nipah virus g glycoprotein immunogenic compositions
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
JP6275641B2 (ja) * 2011-07-20 2018-02-07 ビージーピー プロダクツ ベー ブイ ウイルス抗原およびワクチンの製造方法
CA2850296C (en) 2011-10-03 2021-01-12 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
EP3682897A1 (en) 2012-07-27 2020-07-22 Baxalta GmbH Compositions comprising chimeric ospa molecules and methods of use thereof
KR101980989B1 (ko) 2012-12-20 2019-05-21 화이자 인코포레이티드 당접합 방법
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
KR20150137085A (ko) 2013-03-26 2015-12-08 더 피르브라이트 인스티튜트 안정화된 ｆｍｄｖ 캡시드
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN105828836A (zh) 2013-12-16 2016-08-03 硕腾服务有限责任公司 亨德拉病毒和尼帕病毒g糖蛋白免疫原性组合物
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
US10034934B2 (en) 2014-03-11 2018-07-31 Regents Of The University Of Minnesota Porcine epidemic diarrhea virus vaccines and methods of use thereof
EP3188750B1 (en) 2014-09-03 2020-03-11 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
WO2016050961A1 (en) 2014-10-03 2016-04-07 Intervet International B.V. Broad-spectrum vaccine against avian reovirus
EP3207055A1 (en) 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2834880T3 (es) 2015-03-10 2021-06-21 Bio Rad Laboratories Prueba combinada de sífilis treponémica y no treponémica
RU2692923C2 (ru) 2015-05-04 2019-06-28 Пфайзер Инк. Конъюгаты полисахарида стрептококка группы В и белка, способы получения конъюгатов, иммуногенные композиции, содержащие конъюгаты, и их применения
KR20180052124A (ko) 2015-09-03 2018-05-17 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
CA3033759C (en) 2016-08-17 2022-06-14 Pharmaq As Sea lice vaccine
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
JP7317005B2 (ja) 2017-09-18 2023-07-28 バイエル・ヘルスケア・エルエルシー Ｎ－メチルグルカミドとその誘導体を使用したウイルスの不活化方法
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
JP2023538736A (ja) 2020-08-26 2023-09-11 ファイザー・インク Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
WO2022136505A1 (en) 2020-12-23 2022-06-30 Xenothera Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherapy
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
EP0047480B1 (en) * 1980-09-05 1986-02-05 Institut Armand Frappier Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
GB2104527B (en) * 1981-08-24 1985-10-02 Vilas V Likhite Antingens as immunostimulant adjuvants
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
EP0142193A1 (en) * 1983-10-22 1985-05-22 Akzo N.V. Preparation of immunogens consisting of antigens and/or antigenic determinants bound to glycoside-containing carriers
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DE3617978A1 (de) * 1986-05-28 1987-12-03 Bayer Ag Verzweigte thermoplastische polycarbonate mit verbessertem schutz gegen uv-licht
US6578143B1 (en) * 1998-12-18 2003-06-10 Qualcomm Incorporated Method for negotiating weakened keys in encryption systems
FR2788649A1 (fr) * 1999-01-18 2000-07-21 Schlumberger Systems & Service Procede de chargement securise de donnees entre des modules de securite
FI20075083A0 (fi) * 2007-02-06 2007-02-06 Nokia Corp Ilmaisumenetelmä ja -laite monivuo-MIMOa varten

Also Published As

Publication number Publication date
FI86801C (fi) 1992-10-26
AU590904B2 (en) 1989-11-23
NZ213899A (en) 1988-10-28
JPH07116056B2 (ja) 1995-12-13
WO1987002250A1 (en) 1987-04-23
PT81384A (en) 1985-11-01
PT81384B (pt) 1987-11-11
FI854158A0 (fi) 1985-10-23
ES8701497A1 (es) 1986-12-01
EP0180564B1 (en) 1991-07-17
EP0242380A1 (en) 1987-10-28
FI86801B (fi) 1992-07-15
AU589915B2 (en) 1989-10-26
ATE65186T1 (de) 1991-08-15
EP0180564A2 (en) 1986-05-07
ZA858157B (en) 1986-06-25
EP0242380B1 (en) 1991-04-03
JPH0751514B2 (ja) 1995-06-05
SE8405493D0 (sv) 1984-11-01
CA1275246C (en) 1990-10-16
DK166653B1 (da) 1993-06-28
US5254339A (en) 1993-10-19
NO167076B (no) 1991-06-24
AU4938385A (en) 1986-05-08
DK498585D0 (da) 1985-10-30
IE852672L (en) 1986-05-01
ES548412A0 (es) 1986-12-01
AU6475286A (en) 1987-05-05
EP0180564A3 (en) 1988-06-01
NO167076C (no) 1991-10-02
DE3583485D1 (de) 1991-08-22
CA1275042A (en) 1990-10-09
JPS61129136A (ja) 1986-06-17
DK498585A (da) 1986-05-02
JPS63501078A (ja) 1988-04-21
IE58530B1 (en) 1993-10-06
FI854158L (fi) 1986-05-02

Similar Documents

Publication Publication Date Title
NO854355L (no) Immunogent kompleks, en fremgangsmaate til fremstilling derav og anvendelse av komplekset som en immunstimulator, vaksiner og reagenser.
SE8205892D0 (sv) Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
Holmgren et al. Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids
Yu et al. Isolation and characterization of band 3, the predominant polypeptide of the human erythrocyte membrane
Furukawa et al. Co-purification of galactosyltransferases from chick-embryo liver
Ozaki et al. Direct activation by okadaic acid of the contractile elements in the smooth muscle of guinea-pig taenia coli
Grimbleby et al. Binding of trichloroacetic acid by protein
Ohta et al. The inhibition of Na, K-activated adenosinetriphosphatase by a large molecule derivative of p-chloromercuribenzoic acid at the outer surface of human red cell
Abramson et al. Purification and characterization of the 45,000-dalton fragment from tryptic digestion of (Ca 2++ Mg 2+)-adenosine triphosphatase of sarcoplasmic reticulum
Kimura et al. Isolation of α-connectin, an elastic protein, from rabbit skeletal muscle
Shin et al. Intersubunit disulfides of the follitropin receptor.
Inanami et al. OH-induced free radicals in uridine studied by a method combining ESR, spin-trapping, and liquid chromatography
Barraco et al. Paleobiochemical analysis of an Egyptian mummy
SLOMIANY et al. ABH‐Blood‐Group Antigens and Glycolipids of Human Saliva
Antonyuk et al. Carbohydrate specificity of lectin, purified from the fruiting bodies of Mycena pura/Fr./Kumm. and its use in histochemical investigation
Mikhailov et al. Immunochemical study of gangliosides at the cell surface of sea urchin embryos
CN104730236A (zh) 一种蛋白质固定试剂及其应用
Alvarado Quiroz Characterization of marine exopolymeric substance (EPS) responsible for binding of thorium (IV) isotopes
CN117571983A (zh) 碱性磷酸酶快速标记试剂盒及方法
STOFFEL et al. Covalent binding of photosensitive 1-(12-azido-[9, 10-3H2] oleoyl) glycero-3-phosphocholine (lysolecithin) to human serum high density apolipoproteins
Quiroz Characterization of Marine Exopolymeric Substance (EPS) Responsible for Binding of Thorium (IV) Isotopes
Wallach et al. Membrane “Macromolecules”
Ko Some properties and function of ribosomal proteins from the seeds of Pinus lambertiana
Scouten 8th International symposium on affinity chromatography and biological recognition
Rayet Analysis of the aminoglycosides neomycin and streptomycin

Legal Events

Date Code Title Description
MK1K Patent expired